Publications

2019

Navrazhina K, Hibler BP, Magro CM, Wildman HF. Beach Bummer: A Recurrent Pruritic Buttocks Eruption Following Travel. Am J Med. 2019;132(8):931-933.
Gomez-Arteaga A, Margolskee E, Wei MT, Van Besien K, Inghirami G, Horwitz S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019;60(7):1626-1631.
Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019;10(1):2977.
Martin P, Ruan J, Furman R, Rutherford S, Allan J, Chen Z, et al. A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leuk Lymphoma. 2019;60(12):2917-2921.
Goel R, Chopra S, Tobian AA, Ness PM, Frank SM, Cushing M, et al. Platelet transfusion practices in immune thrombocytopenia related hospitalizations. Transfusion. 2019;59(1):169-176.
Kobayashi S, Contractor T, Vosburgh E, Du Y-, Tang LH, Clausen R, et al. Alleles of Insm1 determine whether RIP1-Tag2 mice produce insulinomas or nonfunctioning pancreatic neuroendocrine tumors. Oncogenesis. 2019;8(3):16.
Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT, et al. Clinicopathologic and genetic characterization of nonacute -mutated myeloid neoplasms. Blood Adv. 2019;3(9):1540-1545.
Toyoda Y, Franck P, Brownstone ND, Lieberman M, Magro CM, Otterburn DM. Apocrine adenocarcinoma in the setting of apocrine hidrocystoma of the leg. Dermatol Online J. 2019;25(6).
Gomes AP, Ilter D, Low V, Rosenzweig A, Shen Z-, Schild T, et al. Dynamic Incorporation of Histone H3 Variants into Chromatin Is Essential for Acquisition of Aggressive Traits and Metastatic Colonization. Cancer Cell. 2019;36(4):402-417.e13.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700